Antileishmanial Drug Class List

Drugs in Drug Class: Antileishmanial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Knight Theraps	IMPAVIDO	miltefosine	CAPSULE;ORAL	204684-001	Mar 19, 2014		RX	Yes	Yes

Market Dynamics and Patent Landscape for Antileishmanial Drugs

Last updated: March 31, 2026

What defines the market landscape for antileishmanial drugs?

The global antileishmanial drug market is driven by the prevalence of leishmaniasis, a neglected tropical disease impacting over 1 billion people in 98 countries, primarily in tropical and subtropical regions, including India, Bangladesh, Sudan, and Brazil. The market is characterized by limited approved treatments, patent expirations on key therapies, and ongoing development of novel agents to address drug resistance and safety concerns.

Market size and growth

• Estimated market value (2022): $300 million
• Compound annual growth rate (CAGR): approximately 5.8% (2022–2027)
• Major markets: India, Latin America, Middle East, and Africa
• Key drivers: rising disease prevalence, increasing R&D investments, and partnership expansion

Key treatments and their market shares

Drug	Delivery Type	Patent Status	Year Approved	Market Share (2022)
Amphotericin B	Liposomal form	Patent expired	1990s	30%
Miltefosine	Oral	Patent expired	2002	25%
Sodium Stibogluconate	Intravenous	Patented, now generic	1930s	20%
Paromomycin	Topical/Injection	Patent expired	1960s	15%
Other experimental drugs	Various	Under patent protection	2010s–present	10%

What are the key market drivers and challenges?

Drivers

• Increasing disease incidence: Leishmaniasis cases grew due to climate change, migration, and urbanization.
• Drug resistance: Resistance to traditional pentavalent antimonials has spurred research and development.
• Lack of effective therapies: Existing drugs have toxicity issues, requiring safer, oral formulations.
• Funding and initiatives: WHO's efforts and global health organizations support drug development projects and access programs.

Challenges

• Limited pipeline: Few drugs in clinical development; most are reformulations or repurposed existing agents.
• Regulatory hurdles: Approval processes focus on safety and efficacy, often in regions with limited regulatory capacity.
• Market access issues: Cost and infrastructure limitations affect drug distribution and uptake.

How does the patent landscape look?

Patent expiration and innovation trends

• Key drugs like amphotericin B and sodium stibogluconate have expired patents, opening markets to generics.
• Miltefosine's patent expired in 2014 in major markets, leading to increased generic competition.
• Recent patent filings relate to new formulations, delivery methods, and combination therapies, primarily dating from 2010 onward.
• Major patent filers include pharmaceutical companies like Gilead Sciences, Cipla, and Seqirus.

Patent filings by year

Year	Number of filings	Main innovations
2010	3	Liposomal formulations, delivery systems
2015	5	Combination therapies, new dosing regimens
2020	2	Targeted delivery mechanisms

Patent expiration impact

• Expiration of key patents facilitates generic manufacturing, lowering treatment costs.
• Innovators focus on novel compounds and formulations to extend patent exclusivity.
• Patent expiries accelerate market entry of generics, influencing pricing strategies and market share shifts.

What are recent R&D trends?

• Focus on oral, low-toxicity drugs to improve compliance.
• Development of combination therapies to address resistance.
• Targeted drug delivery systems to enhance efficacy and reduce side effects.
• Repurposing existing drugs with known safety profiles for new indications.

Leading research initiatives

• Gilead's SCY-078 (Ibrexafungerp), undergoing trials for visceral leishmaniasis.
• DNDi's (Drugs for Neglected Diseases initiative) pipeline includes repurposed antifungals and immunomodulators.
• Collaborations between academia and industry to accelerate preclinical candidate development.

What regulatory and policy factors influence the market?

• WHO guidelines influence drug approval pathways, emphasizing safety and affordability.
• Fast-track approval programs are available in endemic regions for novel therapies.
• Patent policies in countries like India favor generics, affecting exclusivity periods.
• International funding supports clinical R&D, especially in low-resource settings.

Summary

The antileishmanial drug market is expanding modestly, driven by disease prevalence and drug resistance. Patent expirations on conventional therapies have increased the generic market presence, lowering prices but reducing incentives for innovation. Companies are investing in new formulations, combination therapies, and targeted delivery to extend patent life and improve efficacy. Regulatory and funding policies directly impact market dynamics, emphasizing affordability and access.

---

Key Takeaways

• The market is valued at approximately $300 million, with steady growth projected.
• Major drugs like amphotericin B and sodium stibogluconate have expired patents, enabling generics.
• R&D emphasizes oral drugs, combination therapies, and targeted delivery systems.
• Patent filings concentrate on formulations and delivery methods from 2010 onward.
• Market challenges include limited pipelines, regulatory hurdles, and access issues.

---

FAQs

1. What are the leading treatments for leishmaniasis, and what are their patent statuses?
Liposomal amphotericin B, miltefosine, sodium stibogluconate, and paromomycin are primary treatments. Most patents on these drugs have expired, leading to increased generic competition.

2. How does patent expiration impact the market?
Patent expiry allows generic manufacturers to produce cheaper versions, lowering treatment costs and increasing access. It also diminishes revenue for originator companies, pushing them to innovate in formulations and delivery.

3. What innovative approaches are currently in development?
Research focuses on oral formulations, combination therapies to combat resistance, and targeted delivery systems to enhance drug efficacy and safety.

4. Which regions are most affected by leishmaniasis, influencing market dynamics?
India, Brazil, and Sudan experience high disease burdens, shaping demand and R&D priorities centered on these regions.

5. How do regulatory policies affect drug development for leishmaniasis?
Endemic countries often have expedited approval pathways, but regulatory capacity varies. International organizations influence standards and facilitate clinical trials.

---

References

[1] World Health Organization. (2022). Leishmaniasis. WHO.
[2] MarketResearch.com. (2023). Global Antileishmanial Drugs Market Report.
[3] U.S. Patent and Trademark Office. (2023). Patent filings related to leishmaniasis therapies.
[4] DNDi. (2022). Pipeline update. Drugs for Neglected Diseases initiative.
[5] European Patent Office. (2023). Patent landscape reports on neglected tropical disease treatments.